CG Oncology (CGON) Income towards Parent Company (2023 - 2026)

CG Oncology has reported Income towards Parent Company for 4 years, with the latest figure at -$60.1 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 74.42% year-over-year to -$60.1 million; the trailing twelve-month figure through Mar 2026 stood at -$186.5 million (down 76.64% YoY), and the FY2025 full-year result was -$160.8 million, down 82.69% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$60.1 million, down from -$41.3 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$8.7 million in Q1 2023, with the low at -$60.1 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$27.5 million across 4 years, with a median of -$20.4 million in 2024.
• The largest YoY upside for Income towards Parent Company was 29.72% in 2025 against a maximum downside of 119.05% in 2025.
• CG Oncology's Income towards Parent Company stood at -$16.6 million in 2023, then slumped by 92.16% to -$31.8 million in 2024, then slipped by 29.72% to -$41.3 million in 2025, then slumped by 45.68% to -$60.1 million in 2026.
• The last three Income towards Parent Company figures came in at -$60.1 million (Q1 2026), -$41.3 million (Q4 2025), and -$43.7 million (Q3 2025), per Business Quant data.